company
Plasfer Launches Its New Website
Plasfer unveils a redesigned website — clearer, faster and built around its two verticals, with regenerative medicine now front and centre alongside the oncology pipeline.
Engineering platelets into targeted medicines.
Plasfer's PTT platform turns platelets into precision delivery vehicles — for regenerative medicine and oncology.
The Plasfer strategy
One platform, two verticals
Near-term · Revenue engine
PLA-REGEN
Regenerative Medicine
A standardized, ready-to-use platelet preparation delivered as a single kit — engineered to provide a high, controlled essential growth-factors content that conventional PRP cannot guarantee. Lead market: aesthetics, expanding to orthopaedics, ophthalmology and wound care.
Explore PLA-REGENFlagship pipeline · First-in-class
PLA-ONCO / PLA-CHEMO
Oncology
A Trojan-horse approach that turns the tumour's own recruitment of platelets (TCIPA) into a targeted delivery route for anti-cancer payloads. Lead programmes target pancreatic cancer and KRAS-mutant tumours.
Explore oncologySpotlight · Regenerative Medicine
PRP 2.0 — standardized, defined, ready to use.
Autologous PRP is powerful but inconsistent: its composition changes with every patient and every protocol. PLA-REGEN replaces that variability with a single, validated kit and a defined growth-factor profile — the same regenerative rationale, delivered to a reproducible standard.
See how PLA-REGEN worksLatest
News & updates
company
PLA-REGEN: The End of Guesswork in Regenerative Medicine
Conventional PRP is powerful but unpredictable. PLA-REGEN turns it into a standardized, ready-to-use product with a defined growth-factor profile — the same biology, finally to a reproducible standard.
milestone
Plasfer's Platelet Transfer Technology Granted European Patent EP 2 951 292 B1
The European Patent Office has granted Plasfer's key composition-of-matter and process patent, establishing a robust IP moat around the PTT platform across all therapeutic verticals.
Ready to explore a partnership?
We are actively seeking scientific collaborators, CDMOs, clinical partners, and strategic investors.